Wang Weifeng, Huang Guankai, Lin Hansen, Ren Lei, Fu Liangmin, Mao Xiaopeng
Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Front Oncol. 2023 Jan 16;12:1102392. doi: 10.3389/fonc.2022.1102392. eCollection 2022.
Bladder cancer (BC) is a significant carcinoma of the urinary system that has a high incidence of morbidity and death owing to the challenges in accurately identifying people with early-stage BC and the lack of effective treatment options for those with advanced BC. Thus, there is a need to define new markers of prognosis and prediction.
In this study, we have performed a comprehensive proteomics experiment by label-free quantitative proteomics to compare the proteome changes in the serum of normal people and bladder cancer patients-the successful quantification of 2064 Quantifiable proteins in total. A quantitative analysis was conducted to determine the extent of changes in protein species' relative intensity and reproducibility. There were 43 upregulated proteins and 36 downregulated proteins discovered in non-muscle invasive bladder cancer and normal individuals. Sixty-four of these proteins were elevated, and 51 were downregulated in muscle-invasive and non-muscle-invasive bladder cancer, respectively. Functional roles of differentially expressed proteins were annotated using Gene Ontology (GO) and Clusters of Orthologous Groups of Proteins (COG). To analyze the functions and pathways enriched by differentially expressed proteins, GO enrichment analysis, protein domain analysis, and KEGG pathway analysis were performed. The proteome differences were examined and visualized using radar plots, heat maps, bubble plots, and Venn diagrams.
As a result of combining the Venn diagram with protein-protein interactions (PPIs), Chloride intracellular channel 1 (CLIC1) was identified as the primary protein. Using the Gene Set Cancer Analysis (GSCA) website, the influence of CLIC1 on immune infiltration was analyzed. A negative correlation between CD8 naive and CLIC1 levels was found. For validation, immunohistochemical (IHC), qPCR, and western blotting (WB) were performed.Further, we found that CLIC1 was associated with a poor prognosis of bladder cancer in survival analysis.
Our research screened CLIC1 as a tumor-promoting protein in bladder cancer for the first time using serum mass spectrometry. And CLIC1 associated with tumor stage, and immune infiltrate. The prognostic biomarker and therapeutic target CLIC1 may be new for bladder cancer patients.
膀胱癌(BC)是泌尿系统的一种重要癌症,由于准确识别早期膀胱癌患者存在挑战,且晚期膀胱癌患者缺乏有效的治疗选择,其发病率和死亡率很高。因此,需要定义新的预后和预测标志物。
在本研究中,我们通过无标记定量蛋白质组学进行了一项全面的蛋白质组学实验,以比较正常人和膀胱癌患者血清中的蛋白质组变化——总共成功定量了2064种可定量蛋白质。进行了定量分析,以确定蛋白质种类相对强度的变化程度和重现性。在非肌肉浸润性膀胱癌和正常个体中发现了43种上调蛋白和36种下调蛋白。其中64种蛋白在肌肉浸润性和非肌肉浸润性膀胱癌中均升高,51种分别下调。使用基因本体论(GO)和蛋白质直系同源簇(COG)对差异表达蛋白的功能作用进行注释。为了分析差异表达蛋白富集的功能和途径,进行了GO富集分析、蛋白质结构域分析和KEGG途径分析。使用雷达图、热图、气泡图和维恩图对蛋白质组差异进行检查和可视化。
通过将维恩图与蛋白质-蛋白质相互作用(PPI)相结合,确定氯离子细胞内通道1(CLIC1)为主要蛋白质。使用基因集癌症分析(GSCA)网站,分析了CLIC1对免疫浸润的影响。发现CD8幼稚细胞与CLIC1水平呈负相关。为进行验证,进行了免疫组织化学(IHC)、qPCR和蛋白质免疫印迹(WB)。此外,在生存分析中我们发现CLIC1与膀胱癌的不良预后相关。
我们的研究首次使用血清质谱法筛选出CLIC1作为膀胱癌中的一种促肿瘤蛋白。并且CLIC1与肿瘤分期和免疫浸润相关。预后生物标志物和治疗靶点CLIC1可能对膀胱癌患者来说是新的。